BPOM RI Approves Pfizer’s Rimegepant for Acute and Preventive Migraine Treatment

Liputan6.com, Jakarta – The Food and Drug Supervisory Agency of the Republic of Indonesia (BPOM RI) has recently approved Rimegepant made by Pfizer. This drug is an innovative migraine dual therapy for the acute treatment and prevention of episodic migraine in the category of adult patients who experience at least four migraine attacks per month.

Rimegepant, which is approved by BPOM RI, works by inhibiting the Calcitonin Gene-related Peptide (CGRP) receptor. The Rimegepant type is a fast-dissolving tablet.

“With this mechanism, Rimegepant helps patients achieve treatment targets related to acute and preventive migraine treatment so that migraine sufferers can better control their disease,”

“The formulation, namely fast-dissolving tablets, Rimegepant can be consumed without water or liquid. The tablet will dissolve in the mouth by placing it on or under the tongue,” said the official statement received by PT Pfizer Indonesia. Health Liputan6.com on Tuesday, December 19, 2023.

Free of Pain and Migraine Symptoms

Referring to the phase 3 study published in the journal The Lanceta single dose of Rimegepant demonstrated superior percentage relief from pain and the most bothersome migraine symptoms within two hours compared to placebo.

Another study also published in The Lancet title ‘Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial’ showed that Rimegepant given one day at a time was able to provide a significant reduction in the average number of days of migraine attacks per month in weeks 9-12 of the 12 week period when taking this migraine drug when compared with placebo.

2023-12-19 05:47:26
#Migraine #drug #Rimegepant #Pfizer #approved #BPOM #heres #works